Impact BioMedical, INC. Cost of Revenue
Impact BioMedical, INC. (IBO) reported Cost of Revenue of $424.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-03-11
- Impact BioMedical, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $422.00K.
- Impact BioMedical, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $1.00K.
- Impact BioMedical, INC. cost of goods and services sold for the quarter ending 2025-06-30 was $11.00K.
- Impact BioMedical, INC. cost of goods and services sold for the quarter ending 2025-03-31 was -$10.00K.
- Impact BioMedical, INC. cost of goods and services sold for fiscal 2025 was $424.00K.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2025-12-31 | $422.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $423.00K derived: sum of 2 quarters · filed 2026-03-11 | $434.00K derived: sum of 3 quarters · filed 2026-03-11 | $424.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | $1.00K 10-Q · filed 2025-11-07 | $12.00K derived: sum of 2 quarters · filed 2025-11-07 | $2.00K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $11.00K 10-Q · filed 2025-08-14 | $11.00K 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | -$10.00K derived: 10-K 12 month − 3 quarters · filed 2026-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |